Hikal Limited Reports Audited Standalone Financial Results for the Fourth Quarter and Standalone and Consolidated Earnings Results for the Year Ended March 31, 2018
May 09, 2018 at 06:20 am EDT
Share
Hikal Limited reported audited standalone financial results for the fourth quarter and standalone and consolidated earnings results for the year ended March 31, 2018. For the quarter, on standalone basis, the company reported total revenue from operations of INR 3,904.9 million against INR 3,146.9 million a year ago. Profit from ordinary activities before tax and exceptional items was INR 391.9 million against INR 321.2 million a year ago. Profit before tax was INR 391.9 million against INR 321.2 million a year ago. Profit was INR 253.4 million or INR 3.13 per basic and diluted share against INR 289.3 million or INR 3.51 per basic and diluted share a year ago. EBITDA up 23% INR 710 million as compared to INR 580 million in the corresponding period of the previous year.
For the year, on standalone basis, the company reported total revenue from operations of INR 13,000.9 million against INR 10,339.6 million a year ago. Profit from ordinary activities before tax and exceptional items was INR 1,115.0 million against INR 832.3 million a year ago. Profit before tax was INR 1,115.0 million against INR 832.3 million a year ago. Profit was INR 772.3 million or INR 9.40 per basic and diluted share against INR 706.8 million or INR 8.55 per basic and diluted share a year ago. EBITDA up 23% INR 2,420 million as compared to INR 1,970 million in the corresponding period of the previous year.
For the year, on consolidated basis, the company reported total revenue from operations of INR 13,000.9 million against INR 10,339.6 million a year ago. Profit from ordinary activities before tax and exceptional items was INR 1,115.0 million against INR 845.3 million a year ago. Profit before tax was INR 1,115.0 million against INR 803.2 million a year ago. Profit was INR 772.3 million or INR 9.40 per basic and diluted share against INR 677.7 million or INR 8.20 per basic and diluted share a year ago.
Hikal Limited is an India-based company, which is engaged in the manufacturing of various chemical intermediates, specialty chemicals, active pharma ingredients and contract research activities. The Pharmaceuticals segment produces active pharmaceutical ingredients. Its facilities are in Jigani, Bangalore and Panoli, Gujrat. The Crop protection segment produces pesticides and herbicides. Its facilities are in Taloja, Mahad, Maharashtra and Panoli, Gujarat. Its human health product categories include anti-convulsant, anti-emetic, anti-histaminic, anti-depressant, anti-psychotic, anti-lipemic, hemorheologic, anti-diabetic, anti-thrombotic, anti-viral, anti-inflammatory, analgesic and anti-parasitic. Its animal health product categories include anti-tick, anti-parasitic, analgesic, anabolic steroids, female sex hormone and NSAID. Its crop protection product categories include algaecide, biocide, fungicide, herbicide, insecticide and intermediate.
Hikal Limited Reports Audited Standalone Financial Results for the Fourth Quarter and Standalone and Consolidated Earnings Results for the Year Ended March 31, 2018